Surgeons and clinical researchers: We are pleased to announce the call for study sites to join the Geistlich Pharma AG’s Chondro-Gide US Pivotal Trial.
The study has a unique design that will evaluate outcomes of Chondro-Gide use to treat large focal knee defects. Contact us via email at secure@telospartnersllc.com.
With more than 80 peer reviewed publications, the Geistlich AMIC® Chondro-Gide® for the knee is the most widely published product in its category. AMIC®, or Autologous Matrix-Induced Chondrogenesis, performed in conjunction with Chondro-Gide®, a bioderived collagen membrane, is a 1-step treatment for repairing cartilage lesions.
Geistlich Surgery is now pleased to announce the SECURE study, a pivotal trial that will be conducted to secure regulatory clearance/approval in the United States. Geistlich Surgery is actively recruiting qualified clinical study sites to participate in this ground breaking initiative!
Click here for full details! (PDF format)
Read next article: Cracking the Commercialization Code; a JLABS Webinar